339 related articles for article (PubMed ID: 31064781)
1. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
4. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
6. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
[TBL] [Abstract][Full Text] [Related]
8. A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Zitzmann-Kolbe S; Kristian A; Zopf D; Kamfenkel C; Politz O; Ellingsen C; Hilbig J; Juul MU; Fonslet J; Nielsen CH; Schatz CA; Bjerke RM; Cuthbertson AS; Mumberg D; Hagemann UB
Mol Cancer Ther; 2023 Sep; 22(9):1073-1086. PubMed ID: 37365121
[TBL] [Abstract][Full Text] [Related]
9. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
10. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
[TBL] [Abstract][Full Text] [Related]
11. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
14. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
16. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
17.
Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
[TBL] [Abstract][Full Text] [Related]
18. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
20. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
